DrugDashboards

everolimus

everolimus · EVEROLIMUS 10 mg/1 · Tablet · Oral · Novugen Pharma (USA) LLC.

NDC 82293-0033-31 · 1 POUCH in 1 CARTON / 3 BLISTER PACK in 1 POUCH / 10 TABLET in 1 BLISTER PACK · ANDA · View full market →

The short version

7 companies supply this market — a reasonable cushion if one runs into trouble.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

All Part D pricing →

Matched to CMS's representative package for this drug (NDC 00078-0567-51) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.

ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of saleⓘ
$687.56per unit
middle half $687.56–$687.56 · 2 plans · Apr 1, 2026
Est. net of rebatesⓘ
≈ $687.56
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
0%of plans cover it
tier 1 · prior auth 100% · step therapy 0% · qty limit 100%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for everolimus (oral solid) in the next 90 days

sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill · avg $3,530.92 per prescription
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
ANDA219955
TE code
AB
Approval date
Oct 30, 2025
Patents / exclusivity
None on file

Shortage history

  • Planned discontinuation — Everolimus, Tablet, 10 mg (NDC 0093-7769-24)Mar 2, 2026
  • Planned discontinuation — Everolimus, Tablet, 2.5 mg (NDC 0093-7766-24)Mar 2, 2026
  • Planned discontinuation — Everolimus, Tablet, 5 mg (NDC 0093-7767-24)Mar 2, 2026
  • Planned discontinuation — Everolimus, Tablet, 7.5 mg (NDC 0093-7768-24)Mar 2, 2026
  • Planned discontinuation — Everolimus, Tablet, 2.5 mg (NDC 49884-119-91)Jan 6, 2026
  • Planned discontinuation — Everolimus, Tablet, 5 mg (NDC 49884-125-91)Jan 6, 2026
  • Planned discontinuation — Everolimus, Tablet, 7.5 mg (NDC 49884-127-91)Jan 6, 2026

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of everolimus (Tablet)

LabelerStrengthFirst seenLast seen
Ascend Laboratories, LLCEVEROLIMUS .5 mg/1Jul 15, 2026Sep 2, 2026
Ascend Laboratories, LLCEVEROLIMUS .25 mg/1Jul 15, 2026Sep 2, 2026
Ascend Laboratories, LLCEVEROLIMUS 1 mg/1Jul 15, 2026Sep 2, 2026
Ascend Laboratories, LLCEVEROLIMUS .75 mg/1Jul 15, 2026Sep 2, 2026
Aurobindo Pharma LimitedEVEROLIMUS 1 mg/1Jul 15, 2026Sep 2, 2026
Aurobindo Pharma LimitedEVEROLIMUS .25 mg/1Jul 15, 2026Sep 2, 2026
Aurobindo Pharma LimitedEVEROLIMUS .5 mg/1Jul 15, 2026Sep 2, 2026
Aurobindo Pharma LimitedEVEROLIMUS .75 mg/1Jul 15, 2026Sep 2, 2026
Biocon Pharma Inc.EVEROLIMUS 5 mg/1Jul 15, 2026Sep 2, 2026
Biocon Pharma Inc.EVEROLIMUS .75 mg/1Jul 15, 2026Sep 2, 2026
Biocon Pharma Inc.EVEROLIMUS .5 mg/1Jul 15, 2026Sep 2, 2026
Biocon Pharma Inc.EVEROLIMUS 10 mg/1Jul 15, 2026Sep 2, 2026
Biocon Pharma Inc.EVEROLIMUS 1 mg/1Jul 15, 2026Sep 2, 2026
Biocon Pharma Inc.EVEROLIMUS .25 mg/1Jul 15, 2026Sep 2, 2026
Biocon Pharma Inc.EVEROLIMUS 7.5 mg/1Jul 15, 2026Sep 2, 2026
Biocon Pharma Inc.EVEROLIMUS 2.5 mg/1Jul 15, 2026Sep 2, 2026
Breckenridge Pharmaceutical, Inc.EVEROLIMUS 2.5 mg/1Jul 15, 2026Sep 2, 2026
Breckenridge Pharmaceutical, Inc.EVEROLIMUS 5 mg/1Jul 15, 2026Sep 2, 2026
Breckenridge Pharmaceutical, Inc.EVEROLIMUS 10 mg/1Jul 15, 2026Sep 2, 2026
Breckenridge Pharmaceutical, Inc.EVEROLIMUS 7.5 mg/1Jul 15, 2026Sep 2, 2026
CivicaScript, LLCEVEROLIMUS 5 mg/1Jul 15, 2026Sep 2, 2026
CivicaScript, LLCEVEROLIMUS 10 mg/1Jul 15, 2026Sep 2, 2026
CivicaScript, LLCEVEROLIMUS 2.5 mg/1Jul 15, 2026Sep 2, 2026
CivicaScript, LLCEVEROLIMUS 7.5 mg/1Jul 15, 2026Sep 2, 2026
Hikma Pharmaceuticals USA Inc.EVEROLIMUS .25 mg/1Jul 15, 2026Sep 2, 2026
Hikma Pharmaceuticals USA Inc.EVEROLIMUS .5 mg/1Jul 15, 2026Sep 2, 2026
Hikma Pharmaceuticals USA Inc.EVEROLIMUS 2.5 mg/1Jul 15, 2026Sep 2, 2026
Hikma Pharmaceuticals USA Inc.EVEROLIMUS 5 mg/1Jul 15, 2026Sep 2, 2026
Hikma Pharmaceuticals USA Inc.EVEROLIMUS 1 mg/1Jul 15, 2026Sep 2, 2026
Hikma Pharmaceuticals USA Inc.EVEROLIMUS 10 mg/1Jul 15, 2026Sep 2, 2026
Hikma Pharmaceuticals USA Inc.EVEROLIMUS .75 mg/1Jul 15, 2026Sep 2, 2026
Hikma Pharmaceuticals USA Inc.EVEROLIMUS 7.5 mg/1Jul 15, 2026Sep 2, 2026
Natco Pharma LimitedEVEROLIMUS .75 mg/1Jul 15, 2026Sep 2, 2026
Natco Pharma LimitedEVEROLIMUS 1 mg/1Jul 15, 2026Sep 2, 2026
Natco Pharma LimitedEVEROLIMUS .25 mg/1Jul 15, 2026Sep 2, 2026
Natco Pharma LimitedEVEROLIMUS .5 mg/1Jul 15, 2026Sep 2, 2026
Natco Pharma LimitedEVEROLIMUS 2.5 mg/1Jul 15, 2026Sep 2, 2026
Natco Pharma LimitedEVEROLIMUS 5 mg/1Jul 15, 2026Sep 2, 2026
Natco Pharma LimitedEVEROLIMUS 7.5 mg/1Jul 15, 2026Sep 2, 2026
Natco Pharma LimitedEVEROLIMUS 10 mg/1Jul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "everolimus — NDC 82293-0033-31," retrieved September 3, 2026, https://drugdashboards.com/drug/82293003331.

Free to cite with attribution — see how the data is put together.